Free tool
Rare disease stocks
We cover 8 companies grouped under the Rare disease theme. The median market value in the group is $1.96B. Across the group, the median move over the past trading day is +0.10%. Price change over the past year runs from +2.9% to +2802.9% across the middle 80 percent of the group, with a median of +117.5%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
8 of 268 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| 0HNC.L | BioMarin Pharmaceutical Inc. | $9.93B | Mid cap | +15.03% |
| CRNX | Crinetics Pharmaceuticals, Inc. | $9.00B | Mid cap | +179.08% |
| AMLX | Amylyx Pharmaceuticals, Inc. | $4.13B | Mid cap | +292.38% |
| CPRX | Catalyst Pharmaceuticals Inc | $3.85B | Mid cap | +55.97% |
| 0IIM.L | Esperion Therapeutics, Inc. | $61.56M | Micro cap | +44.65% |
| VYNE | VYNE Therapeutics Inc | $19.07M | Micro cap | +8660.74% |
| CMMB | Chemomab Therapeutics Ltd. | $16.85M | Micro cap | −25.57% |
| GLMD | Galmed Pharmaceuticals Ltd. | $4.48M | Micro cap | +211.51% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.